The US Food and Drug Administration appears to have closed the door to further debate on the approvability of Intarcia Therapeutics’s ITCA 650, an exenatide implant for type 2 diabetes.
The drug-device combination product’s benefit-risk profile is inadequate to support approval, Principal Deputy Commissioner (PDC) Namandjé Bumpus said.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?